Dr Neill Liptrott BSc, MSc, PhD, FHEA, FRSB
Reader in Pharmacology & Immunocompatibility Pharmacology & Therapeutics
- Work email Neill.Liptrott@liverpool.ac.uk
- Personal WebsiteThe Immunocompatibility Group
Our research aims to understand the concepts and mechanisms which underly the interface of advanced materials and complex medicines with the immune system; to support their translation to clinical use and gain insight into the fundamental biology behind them. We use advanced techniques and technologies to explore and investigate these areas of research as well as developing new techniques to address gaps in the characterisation knowledge base. To date, we have worked with a wide variety of nanotherapeutics from lipidic nanoparticles to polymeric and from virosomes to exosomes for the delivery of diagnostics, small molecules, biopharmaceuticals, biopolymers and nucleic acids. Our work is supported by funds from bodies including, but not limited to, the European Commission, Wellcome Trust, NIH and Kidney Research UK.
In addition to our academic research, we also offer our services and consulting to developed of nanobiomaterials, advanced therapeutics, and complex medicines. This is via the Nanotherapeutics Hub, based in the Centre of Excellence fof Long-acting Therapeutics (CELT), were we can offer support in areas of immunology (e.g., immune cell responses, mixed lymphocyte reactions, immune cell function), haematology (e.g., haemolysis, comlpement activation, platelet activation, coagulation), and cellular health (e.g., cytotoxicity, cell death pathways, bystander responses to cell death/indirect immune stimulation). Examples of our assay capabilities may be found here
Advanced therapeutics, Biomaterials, and Complex Medicines: assessing their biocompatibility and toxicity.
Nanomaterial behaviour has been demonstrated to differ considerably from larger bulk material. The production and use of engineered nanomaterials is constantly expanding, but there remain uncertainties surrounding the potential risks posed to human health and environment. The size of nanomaterials influences their toxicity and this has been consistently demonstrated for nanomaterials encountered in workplace environments (e.g. carbon black, polystyrene, titanium dioxide and silver). Nanomaterials vary considerably with respect to their composition, charge, surface area, solubility, crystal structure, surface chemistry and shape.
Many nanomaterials have been shown to interact with the immune system by either stimulating or suppressing various responses through their interaction with proteins found within blood. Many nanomaterials interact with serum proteins such as opsonins (e.g. antibodies, complement) and are rapidly taken up into cells of the mononuclear phagocyte system (e.g. macrophages). Interactions with serum proteins may render nanomaterials antigenic and it has been suggested that functionalisation (e.g. with growth factors, receptors) may induce neutralising antibodies that also recognise the body’s own molecules with implications similar to those for biotechnology-derived therapeutics. We are utilising a number of approaches to understand how nanomaterials interact with biological systems. Identification of these mechanisms may allow rational design of future materials and reduction of unwanted effects; particularly how complex systems can interact, to bring about clinical events, and how inflammation is key to the definition of Adverse Outcome Pathways (AOP)
Interaction of nanomaterials with the human immunological & haematological systems, pathways of cellular uptake of nanoparticles (both receptor and non-receptor mediated), nanotoxicity of nanomaterials and interaction of nanoparticles with plasma proteins (biomolecular corona). immune modulation, hypersensitivity and pseudo allergy related to advanced materials such as liposomes and lipidic nanoparticles, liposomes, polymeric materials, inorganic nanoparticles, virosomes and exosomes and nanobiomaterials.
Keywords: advanced therapies and therapeutics, liposomes, lipidic nanoparticles (LNP), CARPA, pseudoallergy, hypersensitivity, complex medicines, extracellular vesicles, nanomedicines, nanotherapeutics, biocompatibility, immunology, immunotoxicology, intracellular drug delivery (ICD)
- Development of techniques and technologies for the characterisation of nanomaterials.
The field of nanoimmunotoxicology is constantly evolving as new materials are developed. In order to meet these challenges it is necessary to ensure that current techniques and methodologies are sufficient to identify nanomaterial interactions with biological systems that may be undesirable. New characterisation techniques are studied for their utility and introduced into our assay cascade as appropriate. Interaction with agencies such as EMA and FDA are also key in order to stay ahead of what is required from a regulatory perspective.
Impact of immune status on nanomaterial biocompatibility, drug disposition and intracellular pharmacology.
Dysregulation of the immune system is a hallmark of a number of diseases such as HIV. The mechanisms by which the immune system can influence drug disposition are relatively understudied but recent work has highlighted the necessity for examining its impact on pharmacokinetics and pharmacodynamics. A more comprehensive approach in clinical studies will allow better determination of the impact of cytokines on drug disposition. In addition, determining the mechanisms that underpin the differential effects of cytokines across different cell types will clarify the responses reported in these studies. This in turn relates to the biocompatibility of nanomaterials in patients with dysregulated immune systems as in HIV infection, specifically when comparing the response of uninfected vs infected cells.
Cytokines etc. are integral to the successful resolution of many diseases. Data are emerging on a role for regulation of the expression, and activity, of drug transporters and drug metabolising enzymes.. Investigation of the interaction between pharmacological and immunological responses is key to understanding the complex relationships involved in patient response to therapy as well as how they may respond to nanoformulated therapies.
Keywords: immune response, drug disposition, human immune cells
Influence of metabolic profile, nutrient sensing and exogenous factors on immune responses to xenobiotics and exogenous materials.
Activation of immune cells, results in alteration of energy and nutrient requirements in order to provide sufficient energy resource for the cells and biomass for replication and protein synthesis. Upon activation, immune cells increase their uptake of glucose in order to power cellular processes by glycolysis. Glucose uptake is, primarily, accomplished by the glucose uptake transporters GLUT1 and GLUT4. We have shown that the antiretroviral drugs Efavirenz and Lopinavir can inhibit the activation of primary immune cells (T cells and monocyte-derivd macrophages); nanoformulations of these drugs appear to mitigate some of these processes. Work from the group has demonstrated that Efavirenz and Lopinavir can inhibit glucose uptake, altering bioenergetic profiles in immune cells.. We are determining the activity of metabolite transporters in the metabolic responses to immunological challenges and assessing the long-term implications of exposure to xenobiotics on metabolic profiles.
Additionally, other factors within the local environment may influence immune cell behaviour. Exosomes are nano-sized, extracellular vesicles that are involved in intercellular communication and are generally thought to be involved in immune homeostasis. Their presence in, multiple, biological fluids suggests their importance in controlling the immune response. We have shown that the presence of so-called “tolerosomes” in the plasma may dampen the immunological response of human immune cells to pro-inflammatory stimuli. The aim of this work is to ascertain further the impact of tolerosomes on immunological responses to stimuli, as well as engineered nanobiomaterials, to further our understanding of interindividual responses to treatments.
Keywords: immune metabolism, microenvironment, transporters
Research Group Membership
Building a UK IntraCellular Drug Delivery Centre (ICDDC)
INNOVATE UK (UK)
January 2023 - January 2026
Automated high-resolution microscope platform with robotics to study pharmacodynamics in 3D cell cultures
MEDICAL RESEARCH COUNCIL
November 2022 - March 2023
A game changer for the treatment of osteoarthritis: a cost effective combined advanced therapy to treat knee osteoarthritis (SINPAIN)
UK RESEARCH AND INNOVATION
May 2022 - October 2026
Safety Testing In The Life Cycle Of Nanotechnology-Enabled Medical Technologies For Health (SAFE-N-MEDTECH)
April 2019 - September 2023
Regulatory Science Framework for Nano(bio)material-based Medical Products and Devices (REFINE)
December 2017 - February 2022
Assessing the therapeutic effects of renal regenerative medicine therapies using a suite of in vitro assays
CHILDRENS RESEARCH FUND (UK)
February 2021 - October 2021
European Nanotechnology Characterisation Laboratory
May 2015 - December 2019
Developing novel tools and technologies to assess the safety and efficacy of cell-based regenerative medicine therapies, focusing on kidney disease RenalToolBox
November 2018 - April 2023
Investigating how cell based regenerative medicine therapies modulate T-cells and macrophages to ameliorate acute kidney injury
KIDNEY RESEARCH UK (UK)
November 2018 - September 2021
Exploring how cell therapies ameliorate renal damage
MERSEY KIDNEY FIRST (UK)
October 2018 - September 2021
Long acting NRTI therapies for HIV
NATIONAL INSTITUTES OF HEALTH (USA)
July 2017 - June 2023
Multi-modal high resolution preclinical PET+SPECT+CT scanner
WELLCOME TRUST (UK)
July 2018 - June 2023
Bioengineered substrates for human pluripotent stem cell culture
WELLCOME TRUST (UK)
November 2016 - October 2018
Investigation of the use of nanotechnology to reduce the side effects associated with antiretroviral protease inhibitors
BRITISH SOCIETY FOR ANTIMICROBIAL CHEMOTHERAPY (UK)
May 2015 - December 2016
Characterising the influence of nanoparticle characteristics on their interference/ interaction with endotoxin
ROYAL SOCIETY (CHARITABLE)
October 2015 - September 2016
Prof. Yvonne Perie
Project: Structure-activity relationships between liposomes and complement activation
External: University of Strathclyde
Prof . Rongjun Chen
Project: Development of, immunologically silent, PEG-alternatives
External: Imperial College London
Prof. Kirill Afonin
Project: Inflammasome recognition of, and response to, nucleic acid-based nanoparticles
External: UNC Charlotte
Immunocompatibility assessment of, and structural relationships between, nucleic acid nanoparticles.
Dr Rob Vandebriel
Project: Immunotoxicological assessment of nanobiomaterials (REFINE)
External: RIVM - National Institute for Public Health
Dr Joe Vetro
Project: Nucleic acid based nano-therapies for cancer
External: University of Nebraska Medical Centre
Research partnership to develop, biocompatible, nucleic acid based therapies for drug resistant cancers.
Prof. Patricia Murray
Project: Assessment of novel model systems to investigate renal inflammation
Dr Bettina Wilm
Project: Impact of extracellular vesicles on macrophage function and phenotype
Prof, Rachel Williams
Project: Biocompatibility of advanced materials, with nano-topography
Dr Tom McDonald
Project: Development of, immunomodulatory, lipidic nanoparticle delivery systems.
Dr Bryant Nelson
Project: Standardsation of immunotoxicological assessment of nanobiomaterials
External: National Institutes of Health (NIH and ASTM
Dr Sven Even Borgos
Project: Interindividual variability in Immunotoxicological responses to nanobiomaterials
Dr Joe Vetro
Project: Immunomodulation of macrohage phenotype using nano-polyplexes
External: University of Nebraska Medical Centre